Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Marijuana (cannabis) has been investigated as a treatment for glaucoma due to its ability to lower intraocular pressure (IOP), which is a key risk factor in the progression of this eye disease. Early studies in the 1970s and 1980s showed that both smoked marijuana and orally administered cannabinoids could reduce IOP for 3-4 hours. However, these effects are short-lived and would require frequent dosing to maintain therapeutic IOP reduction, leading to significant psychoactive side effects and practical concerns. Major ophthalmology organizations, such as the American Academy of Ophthalmology and the American Glaucoma Society, do not recommend marijuana for glaucoma treatment due to the lack of sustained efficacy and the risks associated with chronic use, including cognitive impairment and potential for addiction. Current scientific consensus is that while marijuana can lower IOP temporarily, safer and more effective treatments—such as prescription eye drops and surgical interventions—are available. Thus, the evidence for marijuana as a primary treatment for glaucoma is weak, and its use is not supported by major clinical guidelines.

More about Marijuana
More about Glaucoma

Other ingredients used for Glaucoma

Other health conditions supported by Marijuana

Products containing Marijuana